Compare NNN & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNN | STVN |
|---|---|---|
| Founded | 1984 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Containers/Packaging |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 4.2B |
| IPO Year | 1995 | 2021 |
| Metric | NNN | STVN |
|---|---|---|
| Price | $44.99 | $16.79 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $43.33 | $23.75 |
| AVG Volume (30 Days) | ★ 1.4M | 724.9K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.28% | 0.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $926,213,000.00 | N/A |
| Revenue This Year | $4.85 | $8.42 |
| Revenue Next Year | $5.14 | $9.27 |
| P/E Ratio | ★ $22.01 | $27.15 |
| Revenue Growth | ★ 6.55 | N/A |
| 52 Week Low | $35.80 | $13.91 |
| 52 Week High | $46.03 | $28.00 |
| Indicator | NNN | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 50.18 |
| Support Level | $40.62 | $13.91 |
| Resistance Level | $45.47 | $16.69 |
| Average True Range (ATR) | 0.80 | 0.73 |
| MACD | 0.05 | 0.16 |
| Stochastic Oscillator | 59.43 | 78.24 |
NNN REIT Inc is a real estate investment trust that acquires, owns, invests in, and develops high-quality properties mainly leased under long-term net leases with minimal capital expenditure requirements. The company focuses mainly on retail properties, with a portfolio including convenience stores, automotive service properties, restaurants, theatres, entertainment venues, dealerships, and other retail-related assets. Primary business objectives emphasize retail properties, and it may invest in a wide variety of property and tenant types, leases, mortgages, loans secured by personal property, loans secured by partnership or membership interests, and securities of other REITs or other issuers.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.